In patients with resected stage II–IIIA NSCLC, atezolizumab is the only approved CPI to date, based on the positive results of a phase III trial (IMpower010), demonstrating a DFS benefit compared to the best supportive care: a 34% reduced risk of tumor recurrence or death in the subgroup whose tumors expressed PD-L1 (HR: 0.66; 95% Cl: 0.50; 0.88; p = 0.0039) [27]. The gene discussed is CD274; the disease is neoplasm.